CUDA is a novel and potent inhibitor of sEH (soluble epoxide hydrolase) with potential to be used in cardiovascular disease. It inhibits sEH with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity

Physicochemical Properties

Molecular Formula	C19H36N2O3
Molecular Weight	340.500745773315
Exact Mass	340.272
CAS #	479413-68-8
PubChem CID	22978774
Appearance	White to off-white solid powder
Density	1.0±0.1 g/cm3
Boiling Point	549.4±19.0 °C at 760 mmHg
Flash Point	286.1±21.5 °C
Vapour Pressure	0.0±3.2 mmHg at 25°C
Index of Refraction	1.501
LogP	4.79
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	13
Heavy Atom Count	24
Complexity	342
Defined Atom Stereocenter Count	0
InChi Key	HPTJABJPZMULFH-UHFFFAOYSA-N
InChi Code	InChI=1S/C19H36N2O3/c22-18(23)15-11-6-4-2-1-3-5-7-12-16-20-19(24)21-17-13-9-8-10-14-17/h17H,1-16H2,(H,22,23)(H2,20,21,24)
Chemical Name	12-(cyclohexylcarbamoylamino)dodecanoic acid
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	PPARα; mouse sEH:11.1 nM (IC50); human sEH:112 nM (IC50)
ln Vitro	In COS-7 cells, CUDA (10 μM; 18 hours) stimulates PPARalpha by 6 and 3 times, respectively[2]. In addition to competitively inhibiting Wy-14643 (pirinixic acid) from binding to the PPARalpha ligand binding domain, CUDA does not change the expression of the PPARalpha protein, indicating that it is a PPARalpha ligand[2].
Cell Assay	Western Blot Analysis[2] Cell Types: COS-7 cells Tested Concentrations: 10 μM Incubation Duration: 18 hrs (hours) Experimental Results: Activated PPARα by binding to the ligand binding domain of PPARα.
References	[1]. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol. 2002 May 1;63(9):1599-608. [2]. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther. 2005 Jul;314(1):260-70.
Additional Infomation	12-[(Cyclohexylcarbamoyl)amino]dodecanoic acid is a medium-chain fatty acid.

Solubility Data

Solubility (In Vitro)

DMSO : ~25 mg/mL (~73.42 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 0.5 mg/mL (1.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.9369 mL	14.6843 mL	29.3686 mL
	5 mM	0.5874 mL	2.9369 mL	5.8737 mL
	10 mM	0.2937 mL	1.4684 mL	2.9369 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.